source
- FDA outlines pathway for approval of personalized gene-editing therapiesThe U.S. Food and Drug Administration released a set of recommendations describing how developers can pursue regulatory approval for gene-editing treatments that are customized to a single patient’…
- AstraZeneca’s heart drug Wainua fails late-stage trial, raising 2027 outlook concernsAstraZeneca announced that its experimental heart disease therapy, Wainua, did not meet primary endpoints in a Phase III trial conducted in July. The failure is a setback for the company, whose pi…